Heterogeneity of action potential durations in isolated mouse left and right atria recorded using voltage-sensitive dye mapping.
An imaging system for di-4-ANEPPS (4-[beta-[2-(di-n-butylamino)-6-naphthylvinyl]pyridinium]) voltage-sensitive dye recordings has been adapted for recording from an in vitro mouse heart preparation that consists of both atria in isolation. This approach has been used to study inter- and intra-atrial activation and conduction and to monitor action potential durations (APDs) in the left and right atrium. The findings from this study confirm some of our previous findings in isolated mouse atrial myocytes and demonstrate that many electrophysiological properties of mouse atria closely resemble those of larger mammals. Specifically, we made the following observations: 1) Activation in mouse atria originates in the sinoatrial node and spreads into the right atrium and, after a delay, into the left atrium. 2) APD in the left atrium is shorter than in the right atrium. 3) Sites in the posterior walls have longer APDs than sites in the atrial appendages. 4) Superfusion of this preparation with 4-aminopyridine and tetraethylammonium resulted in increases in APD, consistent with their inhibitory effects on the K+ currents known to be expressed in mouse atria. 5) The muscarinic agonist carbachol shortened APD in all areas of the preparation, except the left atrial appendage, in which carbachol had no statistically significant effect on APD. These results validate a new approach for monitoring activation, conduction, and repolarization in mouse atria and demonstrate that the physiological and pharmacological properties of mouse atria are sufficiently similar to those of larger animals to warrant further studies using this preparation.
Nygren
Anders
A
Whitaker Institute of Biomedical Engineering, PFBG 384, Univ. of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0412, USA.
Lomax
Alan E
AE
Giles
Wayne R
WR
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D004396:Coloring Agents; D006321:Heart / Q000502:physiology*; D006325:Heart Atria; D006329:Heart Conduction System / Q000502:physiology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018721:Muscarinic Agonists / Q000494:pharmacology; D055095:Optics and Photonics; D011188:Potassium / Q000493:pharmacokinetics; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000502:physiology; D012433:Ryanodine / Q000494:pharmacology
D004396:Coloring Agents; D018721:Muscarinic Agonists; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D012433:Ryanodine; D011188:Potassium